Detection of BRAF V600E mutation with thyroid tissue using pyrosequencing: Comparison with PNA-clamping and real-time PCR

American Journal of Clinical Pathology

Volumn 139, Issue 6, 2013, Pages 759-764

  Kang, Seong Ho ^a   Pyo, Ju Yeon ^b   Yang, Seok Woo ^b   Hong, Soon Won ^b  

^a Chosun University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

BRAF; Peptide nucleic acid; Pyrosequencing; Quantification; Sensitivity

Indexed keywords

B RAF KINASE;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PEPTIDE NUCLEIC ACID CLAMPING POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PYROSEQUENCING; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; THYROID CARCINOMA; WILD TYPE;

BRAF; PEPTIDE NUCLEIC ACID; PYROSEQUENCING; QUANTIFICATION; SENSITIVITY;

ADOLESCENT; ADULT; AGED; CARCINOMA; HUMANS; MIDDLE AGED; MUTATION; PEPTIDE NUCLEIC ACIDS; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; REAL-TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; THYROID GLAND; THYROID NEOPLASMS;

EID: 84878394785     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPN3ULH6YWBHPH     Document Type: Article

References (23)

1. Ministry for Health, Welfare and Family Affairs (Korea) 2008 cancer incidence in Korea 1999-2002. http://www.cancer.go.kr/ncic/cics-g/cics-g02/cics- g027/--icsFiles/afieldfile/2009/09/16/aa(aa0606).pdf. Accessed April 16, 2013.
2. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954. (Pubitemid 34716871)
3. Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63:1454-1457. (Pubitemid 36373628)
4. Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab. 2003;88:4393-4397. (Pubitemid 37153748)
5. V600E mutation-prevalent area. Clin Endocrinol (Oxf). 2006;65:660-666.
6. V600E mutation in an FNAB specimen of thyroid nodules. Diagn Mol Pathol. 2008;17:118-125.
7. 600E mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis. Thyroid. 2009;19:137-141.
8. V600E mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab. 2008;93:3943-3949.
9. V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg. 2012;36:310-317.
10. Ito Y, Yoshida H, Maruo R, et al. BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J. 2009;56:89-97.
11. Jin L, Sebo TJ, Nakamura N, et al. BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid. Diagn Mol Pathol. 2006;15:136-143. (Pubitemid 44325474)
12. Tan YH, Liu Y, Eu KW, et al. Detection of BRAF V600E mutation by pyrosequencing. Pathology. 2008;40:295-298. (Pubitemid 351563933)
13. V600E mutation-prevalent area. Head Neck. 2010;32:490-498.
14. Lee HJ, Choi J, Hwang TS, et al. Detection of BRAF mutations in thyroid nodules by allele-specific PCR using a dual priming oligonucleotide system. Am J Clin Pathol. 2010;133:802-808.
15. Orum H. PCR clamping. Curr Issues Mol Biol. 2000;2:27-30.
16. Heid CA, Stevens J, Livak KJ, et al. Real time quantitative PCR. Genome Res. 1996;6:986-994. (Pubitemid 26388091)
17. Packham D, Ward RL, Ap Lin V, et al. Implementation of novel pyrosequencing assays to screen for common mutations of BRAF and KRAS in a cohort of sporadic colorectal cancers. Diagn Mol Pathol. 2009;18:62-71.
18. Jo YS, Li S, Song JH, et al. Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab. 2006;91:3667-3670. (Pubitemid 44402153)
19. Kim KH, Suh KS, Kang DW, et al. Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto's thyroiditis. Pathol Int. 2005;55:540-545.
20. Kim TY, Kim WB, Rhee YS, et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf). 2006;65:364-368.
21. Lee JH, Lee ES, Kim YS, et al. BRAF mutation and AKAP9 expression in sporadic papillary thyroid carcinomas. Pathology. 2006;38:201-204. (Pubitemid 43879713)
22. V600E mutation in ultrasound-guided fine-needle aspiration biopsy samples of thyroid incidentalomas. Clin Endocrinol (Oxf). 2009;70:139-144.
23. Smith RA, Salajegheh A, Weinstein S, et al. Correlation between BRAF mutation and the clinicopathological parameters in papillary thyroid carcinoma with particular reference to follicular variant. Hum Pathol. 2011;42:500-506.